Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PCVX

Vaxcyte Inc

Jun 18 • 04:00PM ET

51.44

+0.77 1.52 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: BNTX MRNA NVAX IBRX BMRN IONS INCY MDGL ALNY VKTX

| Held by: VTI VB IWM VBK XBI VXF IWN IBB VTWO TCAF

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-6.97	Insider Own	2.24%	Shs Outstand	144.31M	Perf Week	8.78%
Market Cap	7.43B	Forward P/E	-	EPS next Y	-6.69	Insider Trans	-2.34%	Shs Float	141.17M	Perf Month	5.45%
Enterprise Value	5.81B	PEG	-	EPS next Q	-2.06	Inst Own	112.20%	Short Float	10.25%	Perf Quarter	-4.71%
Income	-946.53M	P/S	-	EPS this Y	-48.90%	Inst Trans	11.31%	Short Ratio	10.10	Perf Half Y	17.79%
Sales	0.00M	P/B	2.48	EPS next Y	20.20%	ROA	-28.14%	Short Interest	14.47M	Perf YTD	11.49%
Book/sh	20.76	P/C	4.28	EPS next 5Y	-4.13%	ROE	-30.55%	52W High	65.00 -20.86%	Perf Year	54.01%
Cash/sh	12.03	P/FCF	-	EPS past 3/5Y	-17.82% -26.39%	ROIC	-30.47%	52W Low	29.08 76.89%	Perf 3Y	0.57%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.73% 4.30%	Perf 5Y	139.48%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-71.33%	Oper. Margin	-	ATR (14)	2.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.49	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.64	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	7.49	EPS Q/Q	-121.63%	SMA20	5.84%	Beta	1.24	Target Price	109.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	-4.24%	Rel Volume	1.98	Prev Close	50.67
Employees	507	LT Debt/Eq	0.04	Earnings	May 06 AMC	SMA200	4.86%	Avg Volume	1.43M	Price	51.44
IPO	Jun 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-29.40% -	Trades		Volume	2,837,023	Change	1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Reiterated	Needham	Buy	$90 → $110
Sep-12-25	Initiated	Goldman	Neutral	$38
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight
Dec-20-24	Initiated	Goldman	Buy	$135
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

Show Previous Ratings

Jun-02-26 04:05PM	Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults (GlobeNewswire)
May-06-26 04:05PM	Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -9.84%
Apr-07-26 04:05PM	Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-23-26 08:30AM	Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults (GlobeNewswire)
Mar-18-26 07:34PM	Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate (GlobeNewswire)
03:28PM	Loading…
Mar-02-26 03:28PM	Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. (Barchart)
Feb-25-26 08:30AM	Vaxcyte, Inc. Q4 2025 Earnings Call Summary (Moby)
12:08AM	Vaxcyte Q4 Earnings Call Highlights (MarketBeat)
12:03AM	Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ... (GuruFocus.com)
Feb-24-26 04:05PM	Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-19-26 03:42AM	Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials (Insider Monkey)
Feb-18-26 07:39PM	Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating (Insider Monkey) +5.33%
08:36AM	Ovintiv to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-16-26 12:23PM	Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX) (Insider Monkey)
Feb-14-26 03:02PM	Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit (MarketBeat)
04:05PM	Loading…
Feb-11-26 04:05PM	Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines (GlobeNewswire)
Feb-10-26 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 (GlobeNewswire)
Feb-05-26 04:05PM	Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
Feb-02-26 04:05PM	Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +7.15%
Jan-29-26 11:33PM	Vaxcyte Announces Pricing of $550 Million Public Offering (GlobeNewswire)
04:06PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-26-26 03:14AM	Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations (Insider Monkey)
Jan-23-26 10:12AM	Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase (Benzinga)
Jan-22-26 05:00PM	Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine (GlobeNewswire) +7.19%
Dec-22-25 08:19AM	This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. (Barrons.com)
06:50AM	What Makes Vaxcyte (PCVX) So Attractive (Insider Monkey)
Dec-08-25 07:00AM	Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults (GlobeNewswire)
Dec-02-25 09:40AM	Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules (Zacks)
Dec-01-25 04:41PM	Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10 (Investor's Business Daily) -8.24%
12:35PM	Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men (MarketWatch)
09:36AM	Loading…
09:36AM	Moderna Falls as FDA Vows to Impose New Vaccine Requirements (Bloomberg)
Nov-18-25 09:32AM	These 3 Stocks Are Using Buybacks to Signal Market Confidence (MarketBeat)
Nov-10-25 08:16PM	TD Cowen Reiterates "Buy" Rating on Vaxcyte (PCVX) With $50 PT (Insider Monkey) +6.38%
Nov-04-25 04:05PM	Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Oct-08-25 12:57AM	Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) (Insider Monkey)
Sep-30-25 02:49PM	What Does Wall Street Think About Vaxcyte (PCVX)? (Insider Monkey)
08:30AM	Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services (GlobeNewswire)
04:12AM	Vaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine Study (Insider Monkey)
Sep-12-25 08:55AM	TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling (Insider Monkey)
Sep-03-25 07:30AM	Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose (GlobeNewswire)
Aug-06-25 04:05PM	Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) (GlobeNewswire) -9.06%
Jul-31-25 11:35AM	Vaxcyte, Inc. (PCVX)'s VAX-24 Achieves Phase 2 Success in Infants (Insider Monkey)
Jul-16-25 09:38AM	Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) (Insider Monkey)
Jul-08-25 08:17AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
Jul-02-25 02:47AM	Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting (Insider Monkey)
May-27-25 09:08AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
May-09-25 09:03AM	Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? (Insider Monkey)
May-07-25 04:01PM	Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.45%
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-03-25 05:30AM	Franklin Growth Opportunities SMA Q1 2025 Commentary (Seeking Alpha)
May-01-25 08:00AM	Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors (GlobeNewswire)
Apr-30-25 06:33PM	Hope Amidst The Madness As Market Avoids A New Low (Seeking Alpha)
Apr-29-25 08:24PM	Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? (Insider Monkey) +5.68%
Apr-11-25 04:21PM	Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller's Top Stock Pick with Huge Upside Potential (Insider Monkey) +11.27%
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks) -8.96%
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Apr-01-25 12:45PM	Vaxcyte narrow misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI (TipRanks) -14.65%
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
07:19AM	Vaxcyte stock sinks despite Phase II IPD vaccine trial success (Clinical Trials Arena)
Mar-31-25 05:20PM	Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (Seeking Alpha) -45.64%
04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily)
03:39PM	Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (Seeking Alpha)
09:57AM	Moderna, biotech stocks slide on resignation of FDA official Peter Marks (Yahoo Finance)
09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
07:00AM	Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Mar-30-25 06:30PM	Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now (Insider Monkey)
05:00PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study (GlobeNewswire)
04:08PM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 11:34AM	Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive (Zacks)
09:44AM	Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (InsiderMonkey)
Mar-25-25 08:02AM	Vaxcyte (PCVX) Struggled Amid Political Uncertainty (InsiderMonkey)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-07-25 05:35AM	Goldman Sachs Says Its Time to Pull the Trigger on Healthcare Stocks Here Are 2 Names to Pounce on Now (TipRanks)
Mar-03-25 06:50PM	Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
Feb-26-25 11:03AM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds (Insider Monkey)
07:26AM	Q4 2024 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Financial Health and Promising ... (GuruFocus.com)
Feb-25-25 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
12:30PM	Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily)
Feb-12-25 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-08-25 09:22AM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-06-25 08:20AM	Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 (TipRanks)
07:22AM	Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants (Clinical Trials Arena)
Feb-05-25 08:00AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jan-30-25 04:05PM	Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-18-25 05:50PM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? (Insider Monkey)
Dec-23-24 10:11AM	Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-09-24 07:57AM	What Makes Vaxcyte (PCVX) An Investment Bet? (Insider Monkey)
Dec-04-24 10:03AM	Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants (Clinical Trials Arena)
Dec-03-24 08:00AM	Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Nov-27-24 09:29AM	Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug (Insider Monkey)
Nov-12-24 07:30AM	Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs (GlobeNewswire)
Nov-06-24 12:09AM	Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight (GuruFocus.com)
Nov-05-24 04:01PM	Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-24 09:13AM	Should You Consider Investing in Vaxcyte (PCVX)? (Insider Monkey)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Co-FounderMr. Grant E. Pickering M.B.A.

President & CFOMr. Andrew L. Guggenhime M.B.A.

M.S.Mr. James T. Wassil M.B.A.

Senior VPMr. Mikhail Eydelman J.D.

Chief Technical Operations OfficerMr. Harp Dhaliwal M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 18 '26	Option Exercise	1.79	225	403	497,164	Jun 18 08:08 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 18 '26	Sale	52.50	22,461	1,179,205	474,703	Jun 18 08:08 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 18 '26	Sale	52.50	2,000	105,000	135,215	Jun 18 08:08 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '26	Option Exercise	5.35	10,000	53,500	114,395	Jun 18 08:07 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '26	Sale	53.00	10,000	530,000	104,395	Jun 18 08:07 PM
GUGGENHIME ANDREW	Officer	Jun 18 '26	Proposed Sale	53.00	10,000	530,000		Jun 18 04:12 PM
PICKERING GRANT	Officer	Jun 18 '26	Proposed Sale	52.50	24,461	1,284,205		Jun 18 04:11 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jun 01 '26	Sale	49.52	2,250	111,416	158,494	Jun 03 04:59 PM
Wassil Jim	Officer	Jun 01 '26	Proposed Sale	51.01	2,250	114,772		Jun 01 04:26 PM
Wassil Jim	CHIEF OPERATING OFFICER	May 01 '26	Sale	56.83	2,250	127,870	160,744	May 01 05:37 PM
Wassil Jim	Officer	May 01 '26	Proposed Sale	57.26	2,250	128,835		May 01 04:17 PM
Cowan Elvia	SVP, Finance & CAO	Apr 07 '26	Option Exercise	25.92	3,000	77,760	31,975	Apr 08 04:32 PM
Cowan Elvia	SVP, Finance & CAO	Apr 07 '26	Sale	60.00	3,000	180,000	28,975	Apr 08 04:32 PM
Cowan Elvia	Officer	Apr 07 '26	Proposed Sale	60.00	3,000	180,000		Apr 07 04:24 PM
Wassil Jim	CHIEF OPERATING OFFICER	Apr 01 '26	Sale	58.43	2,250	131,476	162,994	Apr 03 04:06 PM
Wassil Jim	Officer	Apr 01 '26	Proposed Sale	58.11	2,250	130,748		Apr 01 04:08 PM
Cowan Elvia	SVP, Finance & CAO	Mar 17 '26	Sale	55.57	1,892	105,147	28,975	Mar 18 07:03 PM
Cowan Elvia	Officer	Mar 17 '26	Proposed Sale	55.89	1,892	105,744		Mar 17 04:16 PM
Cowan Elvia	SVP, Finance & CAO	Mar 11 '26	Option Exercise	25.92	2,500	64,800	33,367	Mar 11 05:23 PM
Cowan Elvia	SVP, Finance & CAO	Mar 11 '26	Sale	58.59	2,500	146,482	30,867	Mar 11 05:23 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 10 '26	Sale	58.88	7,395	435,440	166,818	Mar 11 05:23 PM
Cowan Elvia	Officer	Mar 11 '26	Proposed Sale	58.62	2,500	146,550		Mar 11 04:06 PM
Wassil Jim	Officer	Mar 10 '26	Proposed Sale	58.47	7,395	432,386		Mar 10 04:12 PM
Cowan Elvia	SVP, Finance & CAO	Feb 26 '26	Option Exercise	25.92	7,716	199,999	31,931	Mar 02 08:08 PM
Dhaliwal Harpreet S.	Chief Technical Ops Officer	Dec 31 '25	Sale	46.69	9,743	454,891	23,928	Jan 02 04:21 PM
HARPREET DHALIWAL	Officer	Dec 31 '25	Proposed Sale	46.69	9,743	454,893		Dec 31 04:32 PM
Cowan Elvia	SVP, FINANCE	Dec 23 '25	Sale	47.92	11,623	556,972	14,534	Dec 29 05:49 PM
ELVIA COWAN	Officer	Dec 23 '25	Proposed Sale	47.92	11,623	556,972		Dec 23 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PCVX

Vaxcyte Inc

Upgrade your Finviz experience